KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated ...

Booster Therapeutics has announced its inception to develop a new class of proteasome activator medicines for ...

The Cardiovascular and Renal Drugs Advisory Committee voted 10-6 in support of Stealth’s elamipretide for the ultra-rare ...

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

XtalPi's AI biologics discovery platform, XtalFold, has been licensed to Janssen Biotech for advanced biotherapeutics ...

The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s ...

Boehringer Ingelheim and Circle Pharma have signed a partnership and licence agreement focused on developing a new cancer ...

Plaque psoriasis is a chronic condition that affects millions yet is often misunderstood or underappreciated in terms of its ...

High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.

At CPHI Europe, Angela Vollstedt, global director of Cell & Gene Therapies at Novartis discussed scale up strategies for cell ...

Patient recruitment is a critical yet challenging phase in clinical trials. EMIS has been lauded for its significant ...

The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer ...